This site is intended for healthcare professionals only

Diabetes &
Primary Care


Share this article

PCDS Newsletter: Report from the 69th Scientific Sessions June 5–9 2009, New Orleans, Louisiana

Colin Kenny

Report from the 69th Scientific Sessions June 5–9 2009, New Orleans, Louisiana

This meeting was held over a long weekend in new Orleans, a hot humid city, only partially recovered from Hurricane Katrina. 

The main trials that were presented are summarised below as well as clinical updates discussed at the meeting.

RECORD study
The main message from this study is that although rosiglitazone does increase the risk of heart failure and some fractures, it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs (Home et al, 2009).

BARI 2D trial
No definitive benefit was seen implementing an insulin-sensitising versus an insulin-providing strategy. Despite an overweighting of participants treated with rosiglitazone in this trial, no increased cardiovascular risk was seen, and interestingly, no excess fracture risk was seen in this patient population (Pop-Busui et al, 2009). 

The Look AHEAD trial
For the clinician in practice, the take-home messages in this study are that meal replacements are a valuable adjunctive technique for ongoing weight loss, and physical activity remains essential in successfully managing overweight people with diabetes (Wadden et al, 2009). 

Clinical updates discussed:

  • It was suggested that bariatric surgery should be renamed metabolic surgery as it can resolve diabetes (220000 Americans underwent this surgery last year).
  • Liraglutide may be slightly more effective than exenatide when compared head-to-head (Buse et al, 2009).
  • In the FIELD study there were significantly fewer amputations in the fenofibrate group (Rajamani et al, 2009).
  • Use of aspirin routinely in diabetes is still open to debate. 
  • The results of the ASCEND study will add more evidence to 
  • the debate.
  • Posters confirmed that at least three more dipeptidyl peptidase-4 inhibitors, two more glucagon-like peptide-1 receptor agonists and inhaled insulin are all in phase 2 or phase 3 trials.
  • The American Diabetes Association would like to use HbA1c levels alone to diagnose diabetes. This is still being debated.

Home PD, Pocock SJ, Beck-Nielsen H (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125–35
Pop-Busui R, Lu J, Lopes N et al (2009) Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 14: 1–13
Wadden TA, West DS, Neiberg RH (2009) One-year weight losses in the Look AHEAD study: factors associated with success.Obesity (Silver Spring) 17: 713–22
Buse J, Sesti G, Schmidt WE et al (2009) Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. Diabetes 591-P
Rajamani K, Colman PG, Li LP et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373: 1780–8

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.